AURN001, an allogeneic cell therapy candidate, achieved positive results in a phase 1/2 clinical trial for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release from Aurion Biotech.
“Topline results of the CLARA trial illustrate that even in patients with less severe disease (typical of those in the U.S.), our product candidate AURN001 has the potential to significantly improve visual acuity and central corneal thickness,” Michael Goldstein, MD, MBA, president and chief medical officer of Aurion, told Healio.
AURN001 combines